Terms: = Lymphoma AND CCND3, P30281, 896, ENSG00000112576 AND Treatment
48 results:
1. A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse.
Yan X; Chen B; Jing H; Yang Z; Zhang T; Lin Y; Shi J
J Hematop; 2023 Dec; 16(4):235-240. PubMed ID: 38175437
[TBL] [Abstract] [Full Text] [Related]
2. Deep learning for [
Häggström I; Leithner D; Alvén J; Campanella G; Abusamra M; Zhang H; Chhabra S; Beer L; Haug A; Salles G; Raderer M; Staber PB; Becker A; Hricak H; Fuchs TJ; Schöder H; Mayerhoefer ME
Lancet Digit Health; 2024 Feb; 6(2):e114-e125. PubMed ID: 38135556
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis.
Zhan J; Yang S; Zhang W; Zhou D; Zhao D; Zhang Y; Wang W; Wei C
Future Oncol; 2023 Oct; 19(31):2123-2133. PubMed ID: 37882339
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of response-adapted therapy (RAT) for advanced Hodgkin's lymphoma compared with conventional treatment in India: a Markov-model based analysis.
Goenka L; Kumar SM; Essakky S; Rajasulochana SR; Sivanantham P; Ayiraveetil R; Kar SS; Ganesan P
Leuk Lymphoma; 2023 Dec; 64(13):2188-2194. PubMed ID: 37667967
[TBL] [Abstract] [Full Text] [Related]
5. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
[TBL] [Abstract] [Full Text] [Related]
6. Baseline tumor gene expression signatures correlate with chemoimmunotherapy treatment responsiveness in canine B cell lymphoma.
Dittrich K; Yıldız-Altay Ü; Qutab F; Kwong DA; Rao Z; Nievez-Lozano SA; Gardner HL; Richmond JM; London CA
PLoS One; 2023; 18(8):e0290428. PubMed ID: 37624862
[TBL] [Abstract] [Full Text] [Related]
7. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting ccnd3.
Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
[TBL] [Abstract] [Full Text] [Related]
8. Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders.
Salmerón-Villalobos J; Castrejón-de-Anta N; Guerra-García P; Ramis-Zaldivar JE; López-Guerra M; Mato S; Colomer D; Diaz-Crespo F; Menarguez J; Garrido-Pontnou M; Andrés M; García-Fernández E; Llavador M; Frigola G; García N; González-Farré B; Martín-Guerrero I; Garrido-Colino C; Astigarraga I; Fernández A; Verdú-Amorós J; González-Muñíz S; González B; Celis V; Campo E; Balagué O; Salaverria I
Blood; 2023 Aug; 142(5):434-445. PubMed ID: 37053555
[TBL] [Abstract] [Full Text] [Related]
9. Losing CD45 and various B-cell markers in a case of MYC-driven pediatric high-grade B-cell lymphoma, not otherwise specified that transformed from Burkitt's lymphoma during rituximab-containing treatments: a case report.
Xue X; Fu L; Qiu T; Cao Z; Wang X; Rao W; Luo Y; He L; Feng X
Virchows Arch; 2023 Jul; 483(1):111-116. PubMed ID: 36383247
[TBL] [Abstract] [Full Text] [Related]
10. Role of Local treatment for Oligometastasis: A Comparability-Based Meta-Analysis.
Rim CH; Cho WK; Lee JH; Kim YS; Suh YG; Kim KH; Chie EK; Ahn YC;
Cancer Res Treat; 2022 Oct; 54(4):953-969. PubMed ID: 35989655
[TBL] [Abstract] [Full Text] [Related]
11. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt lymphoma].
Yang P; Dong F; Zhao W; Tian L; Wan W; Li QH; Gao JJ; Ke XY; Wang JJ; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1498-1503. PubMed ID: 34627430
[TBL] [Abstract] [Full Text] [Related]
13. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract] [Full Text] [Related]
14. Primary diffuse large B-cell lymphoma of the major salivary glands: Increasing incidence and survival.
Gupta A; Lee JA; Nguyen SA; Lentsch EJ
Am J Otolaryngol; 2021; 42(3):102938. PubMed ID: 33524741
[TBL] [Abstract] [Full Text] [Related]
15. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Zaborsky N; Steiner M; Weis S; Greil R; Egle A; Melchardt T
ESMO Open; 2021 Feb; 6(1):100012. PubMed ID: 33399078
[TBL] [Abstract] [Full Text] [Related]
16. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.
Ueno H; Yoshida K; Shiozawa Y; Nannya Y; Iijima-Yamashita Y; Kiyokawa N; Shiraishi Y; Chiba K; Tanaka H; Isobe T; Seki M; Kimura S; Makishima H; Nakagawa MM; Kakiuchi N; Kataoka K; Yoshizato T; Nishijima D; Deguchi T; Ohki K; Sato A; Takahashi H; Hashii Y; Tokimasa S; Hara J; Kosaka Y; Kato K; Inukai T; Takita J; Imamura T; Miyano S; Manabe A; Horibe K; Ogawa S; Sanada M
Blood Adv; 2020 Oct; 4(20):5165-5173. PubMed ID: 33095873
[TBL] [Abstract] [Full Text] [Related]
17. National Sjögren's Foundation Survey: Burden of Oral and Systemic Involvement on Quality of Life.
McCoy SS; Bartels CM; Saldanha IJ; Bunya VY; Akpek EK; Makara MA; Baer AN
J Rheumatol; 2021 Jul; 48(7):1029-1036. PubMed ID: 32934136
[TBL] [Abstract] [Full Text] [Related]
18. Non-Classic Signs of Sézary Syndrome: A Review.
Morris L; Tran J; Duvic M
Am J Clin Dermatol; 2020 Jun; 21(3):383-391. PubMed ID: 31953789
[TBL] [Abstract] [Full Text] [Related]
19. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
Mounié M; Costa N; Conte C; Petiot D; Fabre D; Despas F; Lapeyre-Mestre M; Laurent G; Savy N; Molinier L
J Med Econ; 2020 Mar; 23(3):235-242. PubMed ID: 31876205
[No Abstract] [Full Text] [Related]
20. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for treatment of B-Cell lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract] [Full Text] [Related]
[Next]
